Medication info

Pigmeth Tablet 15/850 mg

Prescription medicationTabletExpired
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Ahn-Gook Pharmaceutical Co., Ltd.
Appearance
White to grayish-white rectangular film-coated tablet
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Expired

MFDS item code 201903335 · Approved 2019.05.22

This product's status changed to Expired on 2024.05.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient’s current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Initiate treatment with 1 tablet of this drug daily, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start with their existing doses of pioglitazone and metformin. No studies have examined the safety and efficacy of switching from other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, older adults, debilitated patients, and malnourished patients should not be titrated up to the maximum dose of this drug. After administering this drug to a patient, or when increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Adequate time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG does not worsen, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
Ahn-Gook Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-independent diabetes
  • blood sugar control disorders
  • Type 2 Diabetes
View approved original text

This medication is administered alongside diet and exercise therapy to assist in blood sugar control for patients with Type 2 Diabetes. It is particularly used when blood sugar control is difficult with either Metformin or Pioglitazone monotherapy, and can also serve as an alternative in combination therapy of the two drugs. Additionally, nutritional counseling, weight loss, and regular exercise should accompany the medication to better sustain the treatment effect. This medication helps improve blood sugar control for patients.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient’s current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Initiate treatment with 1 tablet of this drug daily, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start with their existing doses of pioglitazone and metformin. No studies have examined the safety and efficacy of switching from other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, older adults, debilitated patients, and malnourished patients should not be titrated up to the maximum dose of this drug. After administering this drug to a patient, or when increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Adequate time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG does not worsen, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication helps to control blood sugar. However, it should not be used in patients with impaired kidney function or those with severe heart disease. This medication can rarely cause a serious condition called lactic acidosis, which occurs when lactic acid builds up excessively in the body, posing serious risks. Symptoms of lactic acidosis may include vomiting, abdominal pain, muscle pain, and difficulty breathing, and immediate consultation with a physician is required if these symptoms occur. It is also advisable not to take this medication if liver function is poor or if there is excessive alcohol consumption. It may place a burden on the heart, so patients with heart failure should consult a doctor before using this medication. It should not be administered to patients with a history of bladder cancer or active bladder cancer, and if hematuria or urinary disorders occur during treatment, it should be reported to medical staff immediately. Pregnant or breastfeeding women should not take this medication, and its safety and efficacy have not been established in children. Older adults may require dose adjustment and monitoring of kidney function due to decreased kidney function. Regular monitoring of blood sugar, kidney function, liver function, and blood tests is necessary while taking this medication, and if abnormal symptoms arise, a doctor should be notified immediately. Additionally, this medication should be temporarily discontinued before surgery or before examinations using iodine contrast agents, and should only be resumed after confirming normal kidney function post-examination. During treatment, excessive alcohol should be avoided, and due to potential interactions with other medications, patients should discuss all medications they are taking with a doctor or pharmacist. Symptoms of hypoglycemia may occur, so caution is needed when skipping meals or over-exercising. In case of overdose, immediate medical assistance should be sought, and blood dialysis may be necessary if required.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • weakness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 41 more
  • congestive heart failure
  • excessive and rapid weight changes
  • dyspnea
  • edema
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • liver failure
  • indigestion
  • insomnia
  • dry mouth
  • constipation
  • abdominal distention
  • abnormal blood sugar levels
  • arthralgia
  • gastroesophageal reflux disease
  • gastrointestinal air retention
  • elevated serum creatinine
  • increased blood urea
  • macular edema
  • fracture
  • hypoglycemia
  • elevated serum ALT
  • elevated serum bilirubin
  • increased serum creatinine
  • increased blood lactate concentration
  • decreased blood pH

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

White to grayish-white rectangular film-coated tablet

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.